Hemodialysis treatment assistance system

The hemodialysis treatment support system addresses the inaccuracies in existing evaluation methods by using kinetic models to determine peak solute concentrations and assess treatment outcomes, enhancing the accuracy and adaptability of hemodialysis treatment evaluations.

WO2024242176A1PCT designated stage expired Publication Date: 2024-11-28PHYSIOLOGAS TECH INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019067
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current hemodialysis treatment evaluation methods, such as HDP and sf-Kt/V, face challenges in accuracy due to not accounting for body weight and dialyzer removal performance, and are difficult to apply under varying treatment schedules and conditions, leading to potential over- or under-treatment.

Method used

A hemodialysis treatment support system that uses kinetic models to determine peak solute concentrations based on treatment history and future schedules, incorporating dialyzer clearance, treatment time, and body fluid volume, to evaluate treatment outcomes using HDP or sf-Kt/V indices, even under uneven treatment conditions.

Benefits of technology

Improves the accuracy of hemodialysis treatment evaluation by determining peak concentrations and assessing treatment adequacy, allowing for adjustments in treatment schedules to ensure optimal patient care.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024019067_28112024_PF_FP_ABST
    Figure JP2024019067_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a system capable of improving the evaluation accuracy of hemodialysis treatment results. The peak value of the concentration of the designated substance is determined according to a kinetic model on the basis of treatment information including the clearance of the dialyzer used for the hemodialysis treatment of the patient in the designated period, the time and the number of times of each hemodialysis treatment, and the body fluid amount of the patient. On the basis of HDP or sf-Kt / V corresponding to the peak value, the result of hemodialysis treatment on the patient in the designated period is evaluated.
Need to check novelty before this filing date? Find Prior Art

Description

Hemodialysis treatment support system

[0001] The present invention relates to a technique for supporting blood purification treatment by medical professionals.

[0002] A technology for generating a renal failure blood treatment prescription for a patient has been proposed (see, for example, Patent Document 1). Specifically, first, parameters of a kinetic model specific to the patient are identified based on the concentrations of solutes (e.g., urea, β2-M, and / or phosphate) to be removed in blood samples collected multiple times from the patient. Then, the target concentration of the solute in the patient's blood is input into this kinetic model. This results in a treatment prescription that includes the treatment duration, treatment frequency, dialysate flow rate, and / or blood flow rate required to achieve the target solute concentration. Furthermore, the patient's lifestyle is taken into account in the treatment prescription, and the final treatment method is determined.

[0003] On the other hand, there is also an index called HDP, which determines whether dialysis is excessive or insufficient based on the number of dialysis sessions per week and the dialysis time, and an index called sf-Kt / V, which also takes into account body weight and the removal efficiency (clearance) of the dialyzer.These are relatively easy to calculate and use.

[0004] Patent No. 6018567

[0005] Scribner BH, Oreopolus DG: The Hemodialysis product (HDP): A better index of dialysis adequacy than Kt / V. Dial Transplant 31:13-15, 2002 Squared frequency-Kt / V: a new index of hemodialysis adequacy-correlation with solute concentrations by computer simulation, Murakami et al. Renal Replacement Therapy (2019) 5:8 (https: / / doi.org / 10.1186 / s41100-019-0198-7)

[0006] When using a dynamic model, data from blood samples and data measured using sensors related to patient treatment are used, but measurement errors and other factors can reduce the accuracy or precision of the calculation results. HDP does not take into account weight or dialysis removal performance, so values ​​may be significantly off depending on the treatment method and patient. Although sf-Kt / V takes these factors into account, neither HDP nor sf-Kt / V can be applied when treatment times vary for each treatment or when dialysis days vary from week to week.

[0007] Therefore, an object of the present invention is to provide a system that can improve the accuracy of evaluation of the results of hemodialysis treatment.

[0008] The hemodialysis treatment support system of the present invention calculates the peak concentration value of a designated substance according to a kinetic model based on treatment information including the clearance of a dialyzer used in the patient's hemodialysis treatment during a specified period, the duration of each hemodialysis treatment, the number of hemodialysis treatments during the specified period, and the patient's body fluid volume, and evaluates the outcome of the hemodialysis treatment for the patient during the specified period based on the HDP or sf-Kt / V corresponding to the peak value.

[0009] In the hemodialysis treatment support system having the above configuration, it is preferable to evaluate the results of hemodialysis treatment for the patient during at least one of the first designated period and the second designated period based on at least one of first treatment information as the treatment information representing the treatment history of the patient during the first designated period, which is the past designated period, and second treatment information as the treatment information representing the treatment plan for the patient during the second designated period, which is the future designated period.

[0010] In the hemodialysis treatment support system having the above configuration, it is preferable to correct HDP or sf-Kt / V so that the greater the variation (the more uneven the treatment) in at least one of the duration of each hemodialysis treatment, the time interval during which hemodialysis treatment is not performed, and the number of hemodialysis treatments during the specified period, the smaller the HDP or sf-Kt / V.

[0011] In the hemodialysis treatment support system having the above configuration, it is preferable that an evaluation result of the hemodialysis treatment outcome for the patient during the specified period is output to an output interface.

[0012] 1 is a diagram illustrating the configuration of a hemodialysis treatment support system according to an embodiment of the present invention;

[0013] (Configuration) The hemodialysis treatment support system according to one embodiment of the present invention shown in FIG. 1 includes a database 10 , an input interface 11 , an output interface 12 , and a treatment support processing element 20 .

[0014] The database 10 is configured to store and hold measurement results and models representing the patient's condition, which will be described later. The database 10 may be configured as a database server separate from the hemodialysis treatment support system.

[0015] The input interface 11 is configured to include a keyboard, a touch panel, an imaging device, and / or a microphone (voice input device), and is configured to accept input of information about a patient in response to keyboard operations, touches, taps, swipes, pinches, and other operations, gestures, and / or speech by a user such as a medical professional.

[0016] The output interface 12 is composed of a monitor (image display device, touch panel display) and / or a speaker, and is configured to output information to assist users such as medical professionals in treating patients.

[0017] The treatment support processing element 20 is configured with an arithmetic processing device (e.g., a CPU, a processor and / or a processor core), a storage device (memory such as ROM and RAM, HDD, SSD, etc.), an interface circuit, etc. The treatment support processing element 20 is configured so that the arithmetic processing device reads out necessary data and programs (software) from the storage device (which may constitute the database 10) and performs arithmetic processing on the data in accordance with the programs, thereby performing various arithmetic processing operations described below.

[0018] (Function) First treatment information representing the patient's treatment history for a first specified period (e.g., a plurality of days, such as the current day or the week up to the previous day) is acquired through the input interface 11 (FIG. 2 / STEP 11). The first treatment information includes the clearance of the dialyzer used in the patient's hemodialysis treatment, the duration and number of hemodialysis treatment sessions, and the patient's body fluid volume. The duration and number of hemodialysis treatment sessions included in the first treatment information may or may not be uniform.

[0019] Second treatment information representing the patient's treatment schedule for a second specified period (e.g., a plurality of days, such as one week from the current day or the following day), which is a specified future period, is acquired through the input interface 11 (FIG. 2 / STEP 12). Like the first treatment information, the second treatment information includes the clearance of the dialyzer used in the patient's hemodialysis treatment, the duration and number of hemodialysis treatment sessions, and the patient's body fluid volume. The duration and number of hemodialysis treatment sessions included in the second treatment information may or may not be uniform.

[0020] Based on each of the first treatment information and the second treatment information, a peak value of the concentration of a designated substance (e.g., uremic substance and / or uremic toxin substance (e.g., at least one substance selected from K, Ca, Na, phosphate, and free small molecule substances (e.g., urea, creatinine, uric acid)) in each of the first designated period and the second designated period (and a single designated period including the first designated period and the second designated period) is determined according to a kinetic model (FIG. 2 / STEP 14). As the kinetic model, for example, a single-pool model, a two-pool model, or a local blood flow model is adopted. For example, the peak value can be calculated using a kinetic model (see "Kinetic Model for Urea" and "Kinetic Model for β2-microglobulin" in Non-Patent Document 1) according to the method described in "Methods" in Non-Patent Document 1.

[0021] Next, the peak values ​​of the concentration of the designated substance during each of the first and second designated periods are converted to HDP (Hemodialysis Product) or sf-Kt / V (Square Frequency Kt / V) under the condition that the treatment conditions are uniform (FIG. 2 / STEP 16). For example, the peak values ​​can be converted to HDP or sf-Kt / V according to the method described in Non-Patent Document 1 (see, for example, "Fig. 4" in Non-Patent Document 1).

[0022] HDP is calculated according to the relation (1) using the number of dialysis sessions per week n and the dialysis time per session t (hr).

[0023] HDP = n γ t (1<γ, for example, γ=2)...(1).

[0024] Sf-Kt / V is calculated according to the relational expression (2) using the number of dialysis sessions per week n, the dialysis time per session t (hr), clearance K (catalog data), and body weight W (kg).

[0025] Sf-Kt / V=n 2 ・CL・t / (W×0.6×1000) (2).

[0026] The body fluid volume V (mL) can be calculated using a formula other than 0.6 times the body weight. Alternatively, the distribution volume of the substance in question can be used.

[0027] The clearance CL, which indicates the performance of the dialyzer under dialysis conditions, is, for example, B , dialysate flow rate Q D and the value of the coefficient of performance K0A obtained from catalog data, according to the following relational expression (3).

[0028] CL=Q B (1-X) / {(Q B / Q D )-X}, X=exp(K0A(1 / Q B -1 / Q D )) ...(3).

[0029] Table 1 shows the HDP according to the number of dialysis sessions per week n and the dialysis time per session t (hr), as well as the judgment result of whether the patient's dialysis treatment is sufficient (a "*" indicates that the dialysis treatment is sufficient, and no "*" indicates that the dialysis treatment is insufficient).

[0030]

[0031] For Sf-Kt / V, a similar table is calculated for the body fluid volume V calculated from the patient's weight and the clearance CL in treatment for each treatment condition. The patient's body fluid volume V is evaluated as 60% of the patient's weight, and may also be evaluated according to Watson's formulas (41) and (42) using the patient's age, height H (cm), and dry weight DW (kg).

[0032] (When the patient is male) Watson V = 2.447 - 0.09516 × Age + 0.1074 × H + 0.3362 × DW (41).

[0033] (When the patient is female) Watson V = -0.2097 + 0.1069 × H + 0.2466 × DW (42).

[0034] On the other hand, the relational expressions (1) to (3) do not hold under non-uniform treatment conditions because they are based on the assumption that the dialysis time for each session and the dialysis time per week are always the same. These values ​​depend on the peak concentration, not the average value (time average or integral average, etc.) of the solute concentration, so even if the average value is used, they do not hold under non-uniform treatment conditions.

[0035] To solve this problem, we have investigated a method that can determine whether treatment is excessive or insufficient even in uneven treatments.The peak concentration is determined using a pharmacokinetic model that uses a kinetic model, and the peak concentration is converted to HDP or sf-Kt / V based on the standard.

[0036] The results of the patient's hemodialysis treatment are then evaluated for each of the first and second designated periods (FIG. 2 / STEP 18). Specifically, a process is performed to determine whether the patient's HDP is equal to or greater than a predetermined value (e.g., 72) or whether the patient's sf-Kt / V is equal to or greater than a predetermined value (e.g., 23).

[0037] The outcome evaluation results of the hemodialysis treatment for each of the first and second designated periods (and for a single designated period including the first and second designated periods) are output through the output interface 12 (FIG. 2 / STEP 20).

[0038] This allows a user, such as a medical professional, to perceive the appropriateness of hemodialysis treatment during each of the first and second designated periods (as well as a single designated period including the first and second designated periods), and further allows the user to take action, such as changing the hemodialysis treatment schedule (the treatment duration and number of treatments) during the second designated period, if necessary.

[0039] (Other embodiments of the present invention) In the above embodiment, both the first treatment information and the second treatment information are input to the kinetic model, but in other embodiments, only one of the first treatment information and the second treatment information may be input to the kinetic model.

[0040] HDP may be evaluated according to the relationship (11) based on a decreasing function η=f(α)(∂f / ∂α<0)) whose main variables are the dialysis time per session t, the time interval from the end of the previous dialysis session to the start of the current dialysis session, and / or an index value α (e.g., variance and / or standard deviation) representing the variability of the number of dialysis sessions n per week.

[0041] HDP = ηn γ t...(11).

[0042] Sf-Kt / V may be evaluated according to the relational expression (12) based on a decreasing function η = f (α) (∂ f / ∂ α < 0)) whose main variables are the dialysis time per session t, the time interval from the end of the previous dialysis session to the start of the current dialysis session, and / or an index value α (e.g., variance and / or standard deviation) representing the variability in the number of dialysis sessions n per week.

[0043] Sf-Kt / V=η2n 2 ・CL・t / (W×0.006) (12).

[0044] η1, η 2  may be generated using a relationship previously determined by a kinetic model.

[0045] Alternatively, HDP and / or sf-Kt / V may be calculated from the equivalent peak concentration using a kinetic model, i.e., the peak concentration μ when dialysis is performed over an equal dialysis time and at equal dialysis intervals. 1 Then, HDP or sf-Kt / V is determined by the standard equation (13) or (14).

[0046] HDP=f3(μ1) (13).

[0047] sf-Kt / V=f4 (μ1) (14).

[0048] On the other hand, the peak concentration under actual dialysis conditions with uneven dialysis times and intervals can be calculated using a kinetic model (for example, the method described in Non-Patent Document 2). The peak concentration μ2 under actual uneven dialysis times and intervals calculated using this model is substituted into the standard equation expressed by equation (13) or (14) to obtain the converted value of HDP or sf-Kt / V.

[0049] As the function f3 in the reference equation (13), for example, a power function of μ1 may be used approximately as expressed in the following equation (130).

[0050] HDP = a μ1 n ...(130).

[0051] Similarly, as the function f4 in the reference equation (14), for example, a power function of μ1 may be used approximately as expressed in the following equation (140).

[0052] sf-Kt / V=b μ1 n ...(140).

[0053] In this case, a method may be adopted in which the weekly average concentration is used instead of the peak concentrations μ1 and μ2, and the HDP or Sf-Kt / V for unequal dialysis times and dialysis intervals is calculated using the relational equations (equations corresponding to equations (13) and (14)) for equal dialysis times and dialysis intervals in a similar manner.

[0054] 10. Database 11. Input interface 12. Output interface 20. Treatment support processing element.

Claims

1. A hemodialysis treatment support system which calculates the peak concentration of a specified substance according to a kinetic model based on treatment information including the clearance of a dialyzer used in a patient's hemodialysis treatment during a specified period, the duration of each hemodialysis treatment, the number of hemodialysis treatments during said specified period, and the patient's body fluid volume, and evaluates the results of the hemodialysis treatment for said patient during said specified period based on the HDP or sf-Kt / V corresponding to said peak concentration.

2. A hemodialysis treatment support system as described in claim 1, which evaluates the results of hemodialysis treatment for the patient during at least one of the first designated period and the second designated period based on at least one of first treatment information as the treatment information representing the patient's treatment history during the first designated period, which is the past designated period, and second treatment information as the treatment information representing the patient's treatment plan during the second designated period, which is the future designated period.

3. A hemodialysis treatment support system as claimed in claim 1, wherein the HDP or sf-Kt / V is corrected so that the HDP or sf-Kt / V becomes smaller the greater the variation in at least one of the duration of each hemodialysis treatment, the time interval during which no hemodialysis treatment is performed, and the number of hemodialysis treatments in the specified period.

4. A hemodialysis treatment support system according to any one of claims 1 to 3, which outputs an evaluation result of hemodialysis treatment outcome for said patient during said specified period to an output interface.

Citation Information

Patent Citations

  • Treatment prediction and optimization for renal failure blood treatment, especially home hemodialysis

    JP6018567B2

  • Prediction and optimization of serum potassium for renal failure hemodialysis, especially home hemodialysis

    JP2016535644A